Vebreltinib
A tyrosine kinase inhibitor used in cancer treatment
Vebreltinib is a small molecule tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is designed to target specific tyrosine kinases that are involved in the signaling pathways that promote cancer cell proliferation and survival.
Mechanism of Action[edit | edit source]
Vebreltinib functions by inhibiting the activity of certain tyrosine kinases, which are enzymes that play a critical role in the signaling pathways that regulate cell division and survival. By blocking these kinases, vebreltinib can disrupt the growth and spread of cancer cells. This mechanism is particularly effective in cancers where these kinases are overactive or mutated.
Clinical Development[edit | edit source]
Vebreltinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors. These trials are designed to determine the optimal dosing, assess potential side effects, and evaluate the overall therapeutic benefit of the drug.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of vebreltinib includes its absorption, distribution, metabolism, and excretion. Understanding these parameters is crucial for determining the appropriate dosing regimen and predicting potential drug interactions. Vebreltinib is typically administered orally, and its bioavailability, half-life, and metabolic pathways are subjects of ongoing research.
Side Effects[edit | edit source]
As with many targeted cancer therapies, vebreltinib may cause a range of side effects. Common side effects include fatigue, nausea, and skin rash. More serious adverse effects can occur, and patients are monitored closely during treatment to manage any complications that arise.
Research and Future Directions[edit | edit source]
Research on vebreltinib is focused on expanding its use to a broader range of cancers and understanding its role in combination therapies. Scientists are also investigating biomarkers that can predict which patients are most likely to benefit from treatment with vebreltinib.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
